Smoking poses a greater risk of surgery for thyroid eye disease

Article

Former smokers were at higher risk of having to undergo surgery for TED in a recent study, but the risk was lower than that associated with current smoking.

©logoboom /stock.adobe.com
Those who currently smoked were at greater risk of undergoing orbital decompression, strabismus surgery and eyelid recession than those who never smoked. (Image credit ©logoboom /stock.adobe.com)

Researchers from the Departments of Ophthalmology Boston Children’s Hospital, and Massachusetts Eye and Ear, Harvard Medical School, Boston, US, reported that smoking was associated with an increased risk of surgical intervention for treating thyroid eye disease (TED) in the Intelligent Research in Sight (IRIS) Registry.

The authors undertook a retrospective cohort study1 that included adults with Graves’ disease in the IRIS Registry from January 1, 2013, to December 31, 2020. The primary outcome was the need for surgery to treat TED, ie, orbital decompression, strabismus surgery and eyelid recession surgery.

This study included 87,774 patients (mean age, 59 years; 81% women). .

The results showed that current smokers had a greater 5-year cumulative probability, compared with patients who had never smoked, of undergoing orbital decompression (3.7% vs 1.9%; P < 0.001), strabismus surgery (4.6% vs 2.2%; P < 0.001), and eyelid recession (4.1% vs 2.6%; P < 0.001).

After adjusting for demographic factors (age, sex, race, ethnicity, and geographic region), those who currently smoked were at greater risk of undergoing orbital decompression, strabismus surgery and eyelid recession (P < 0.001 for all comparisons) than those who never smoked. Former smokers were at higher risk of having to undergo each of the surgeries, but the risk was lower than that associated with current smoking.

The authors concluded, “Smoking was associated with increased risk of surgical intervention for TED in the IRIS Registry. Former smokers were at a lower risk than current smokers, supporting the role of smoking cessation in lowering the burden of surgical disease at the population level.”

Reference
  1. Oke I, Reshef ER, Elze T, et al. Smoking is associated with a higher risk of surgical intervention for thyroid eye disease in the IRIS Registry. Am J Ophthalmol. 2023;249:174-82; Published online January 19, 2023; DOI: https://doi.org/10.1016/j.ajo.2023.01.020

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
© 2025 MJH Life Sciences

All rights reserved.